Hepatic oncology

Keyphrases

Publications

volume 10, number 4, 2024

Soo Jin Seung, Hasnain Saherawala, Brandon Zagorski, Carman Tong, Howard Lim, Peter Kim, Vladimir Marquez, Sharlene Gill, David Liu, Janine M Davies
Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada. Hepatic oncology 10 (4) (2024)
Soo Jin Seung, Hasnain Saherawala, Brandon Zagorski, Carman Tong, Howard Lim, Peter Kim, Vladimir Marquez, Sharlene Gill, David Liu, Janine M Davies
Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada. Hepatic oncology 10 (4) (2024)

volume 10, number 1, 2023

Abdalla Aly, Nicole Fulcher, Brian Seal, Trang Pham, Yunfei Wang, Scott Paulson, Aiwu R He
Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting. Hepatic oncology 10 (1) (2023)

volume 10, number 2, 2023

Yajing Wang, Zhanqi Wei, Zheng Zhang, Jingyi Xu, Yaqin Wang, Qian Chen, Yuewei Zhang
Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study. Hepatic oncology 10 (2) (2023)

volume 10, number 3, 2023

Alexandra V Kimchy, Harjit Singh, Esha Parikh, Jessica Rosenberg, Kavya Sanghavi, James H Lewis
The predictive value of liver tests for the presence of liver metastases. Hepatic oncology 10 (3) (2023)

volume 9, number 4, 2023

Eduardo Crespo Vallejo, Antonio Hermosín-Peña, Álvaro Villalba, Eduardo Daguer, José Flores, Javier Periañez, Mario Martínez-Galdámez, Ernesto Santos
Uncooled TATO microwave system for liver ablation. Hepatic oncology 9 (4) (2023)
Tasneem Lokhandwala, Abdalla Aly, Eileen Farrelly, Joanne P Willey, Lois E Lamerato, Marcus Healey, Anna D Coutinho, Brian S Seal
Management of hepatocellular carcinoma from diagnosis in routine clinical practice. Hepatic oncology 9 (4) (2023)

volume 9, number 2, 2022

Ellery Altshuler, Mahmoud Aryan, Govind Kallumkal, Hanzhi Gao, Jake Wilson, Ahmed Ouni, Edward De Leo, Wissam Hanayneh, Kelsey Pan
Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma. Hepatic oncology 9 (2) (2022)

volume 9, number 3, 2022

Gokula Kumar Appalanaido, Muhamad Zabidi Ahmad, Syadwa Abdul Shukor, Alex Khoo Cheen Hoe, Manisekar K Subramaniam, Ang Soo Fan, Mohd Zahri Abdul Aziz
Pathological complete response with immunotherapy and brachytherapy to 15 metastatic liver lesions in a single patient. Hepatic oncology 9 (3) (2022)

volume 9, number 1, 2021

volume 8, number 3, 2021

Gerardo Tovar-Felice, Andrés García-Gámez, Virgilio Benito-Santamaría, David Balaguer-Paniagua, Jordi Villalba-Auñón, Jaume Sampere-Moragues
Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. Hepatic oncology 8 (3) (2021)
Abdalla Aly, Melissa Lingohr-Smith, Jay Lin, Brian Seal
Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA. Hepatic oncology 8 (3) (2021)

volume 8, number 4, 2021

volume 8, number 1, 2020

Peter D Block, Brianna Shinn, Jin Hyang Kim, Hie-Won L Hann
Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes. Hepatic oncology 8 (1) (2020)
Meng-Jun Xiong, Chirag R Patel, Upender Manne, Sameer Al Diffalha
Cirrhotomimetic hepatocellular carcinoma: experience of a single institution and review of the literature. Hepatic oncology 8 (1) (2020)
Ana-Maria Bucalau, Illario Tancredi, Martina Pezzullo, Raphael Leveque, Simona Picchia, Jean-Luc Van Laethem, Gontran Verset
Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. Hepatic oncology 8 (1) (2020)

volume 8, number 2, 2020

Diana Julie Leeming, Signe Holm Nielsen, Roslyn Vongsuvanh, Pruthviraj Uchila, Mette Juul Nielsen, Alexander L Reese-Petersen, David van der Poorten, Mohammed Eslam, Detlef Schuppan, Morten Asser Karsdal, Jacob George
Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. Hepatic oncology 8 (2) (2020)
Numbereye Numbere, Dongwei Zhang, Diana Agostini-Vulaj
A rare histologic subtype of hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma: report of a case. Hepatic oncology 8 (2) (2020)

volume 7, number 1, 2020

Christoph Roderburg, Alexander Wree, Münevver Demir, Moritz Schmelzle, Frank Tacke
The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepatic oncology 7 (1) (2020)
Ghassan Abou-Alfa
Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa. Hepatic oncology 7 (1) (2020)
Caitlin Killen
Welcome to Volume 7 of Hepatic Oncology. Hepatic oncology 7 (1) (2020)
Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
JAK/STAT signaling in hepatocellular carcinoma. Hepatic oncology 7 (1) (2020)
Giammaria Fiorentini, Donatella Sarti, Roberto Nani, Camillo Aliberti, Caterina Fiorentini, Stefano Guadagni
Updates of colorectal cancer liver metastases therapy: review on DEBIRI. Hepatic oncology 7 (1) (2020)

volume 7, number 2, 2020

Devis Pascut, Muhammad Yogi Pratama, Claudio Tiribelli
HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance. Hepatic oncology 7 (2) (2020)
Christoph Roderburg, Burcin Özdirik, Alexander Wree, Münevver Demir, Frank Tacke
Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepatic oncology 7 (2) (2020)
Jiuliang Yan, Binghai Zhou, Hui Li, Lei Guo, Qinghai Ye
Recent advances of GOLM1 in hepatocellular carcinoma. Hepatic oncology 7 (2) (2020)
Pierre-Alain Clavien
The future of liver transplantation: an interview with Pierre-Alain Clavien. Hepatic oncology 7 (2) (2020)
Sebastiao N Martins-Filho, Juan Putra
Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review. Hepatic oncology 7 (2) (2020)

volume 7, number 3, 2020

Abdalla Aly, Sarah M Ronnebaum, Dipen Patel, Yunes Doleh, Fernando Concha-Benavente
Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepatic oncology 7 (3) (2020)
Juan Manuel O'Connor, Fernando Sanchez Loria
Towards precision medicine in colorectal cancer liver metastases. Hepatic oncology 7 (3) (2020)
Elisabetta Goio, Luca Ielasi, Francesca Benevento, Matteo Renzulli, Francesco Tovoli
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery. Hepatic oncology 7 (3) (2020)
Kristeen Onyirioha, Sukul Mittal, Amit G Singal
Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepatic oncology 7 (3) (2020)
John C McVey, Kazunari Sasaki, Daniel J Firl
Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepatic oncology 7 (3) (2020)

volume 7, number 4, 2020

Pierre Nahon, Manon Allaire, Jean-Charles Nault, Valérie Paradis
Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. Hepatic oncology 7 (4) (2020)

volume 6, number 1, 2019

Jean-Luc Raoul, Jean-Sébastien Frenel, Judith Raimbourg, Marine Gilabert
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepatic oncology 6 (1) (2019)
Thomas Tu
Journal Watch: Dr Tu looks back at the most important research articles released in 2018 relating to models and biomarkers of hepatocellular carcinoma. Hepatic oncology 6 (1) (2019)

volume 6, number 2, 2019

Sean P Martin, Xin Wei Wang
The evolving landscape of precision medicine in primary liver cancer. Hepatic oncology 6 (2) (2019)
Suemi Yabuta, Yoshihiro Shidoji
Cytoplasmic translocation of nuclear LSD1 (KDM1A) in human hepatoma cells is induced by its inhibitors. Hepatic oncology 6 (2) (2019)

volume 5, number 1, 2018

Shijia Zhu, Yujin Hoshida
Molecular heterogeneity in hepatocellular carcinoma. Hepatic oncology 5 (1) (2018)
Gabriela Kuftinec, Thomas Loehfelm, Michael Corwin, Blythe Durbin-Johnson, MarieChristi Candido, Rebecca Hluhanich, Souvik Sarkar
De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents. Hepatic oncology 5 (1) (2018)
Massimo Colombo, Ana Lleo
The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepatic oncology 5 (1) (2018)
Anne-Laure Védie, Olivier Sutter, Marianne Ziol, Jean-Charles Nault
Molecular classification of hepatocellular adenomas: impact on clinical practice. Hepatic oncology 5 (1) (2018)
Zachary J Brown, Bernd Heinrich, Tim F Greten
Development of shellfish allergy after exposure to dual immune checkpoint blockade. Hepatic oncology 5 (1) (2018)
Celia Sequera, Sara Manzano, Carmen Guerrero, Almudena Porras
How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma. Hepatic oncology 5 (1) (2018)

volume 5, number 2, 2018

Nikolaos Galanakis, Elias Kehagias, Nikolas Matthaiou, Dimitrios Samonakis, Dimitrios Tsetis
Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepatic oncology 5 (2) (2018)
Ratna Kumari, Manoj Kumar Sahu, Anindita Tripathy, Kanishka Uthansingh, Manas Behera
Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepatic oncology 5 (2) (2018)
Leyre Zubiri, José I Bilbao, Javier Rodríguez, Bruno Sangro
Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. Hepatic oncology 5 (2) (2018)